Meeting
2019 ASCO Annual Meeting
Tumor and microenvironment evolution during chemotherapy combine with bevacizumab in colorectal cancer liver metastasis.
Authors
Wangjun Liao
Nanfang Hospital, Nanfang Medical University, Guangzhou, China
Wangjun Liao , Min Shi , Dongqiang Zeng , Na Huang , Yuqi Wang , Jing Li , Chunlin Wang , Xiaoxiang Rong , Yisheng Fang , Siting Zheng , Yichen Xue , Jiao Wang , Jian Guo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Anal Cancer
Citation
J Clin Oncol 37, 2019 (suppl; abstr 3568)
DOI
10.1200/JCO.2019.37.15_suppl.3568
Abstract #
3568
Poster Bd #
60
Abstract Disclosures
Similar Posters
Poster
2019 Gastrointestinal Cancers Symposium
Assessment of systemic and metastatic neutrophilic inflammation in synchronously resected colorectal cancer and liver metastases.
First Author: Colin William Steele
Poster
2018 ASCO Annual Meeting
A randomized phase II study of perioperative chemotherapy plus bevacizumab versus postoperative chemotherapy plus bevacizumab inpatients with upfront resectable hepatic colorectal metastases (APPROACH).
First Author: You Jin Chun
Poster
2018 ASCO Annual Meeting
Outcomes of oxaliplatin-based (Ox) chemotherapy (CT) on R0 resection of colonic liver metastases (CLM).
First Author: Nicholas Adam Bosma
Poster
2018 Gastrointestinal Cancers Symposium
Liver and/or lung metastasectomy after cetuximab or bevacizumab+FOLFIRI chemotherapy in patients (pts) with metastatic colorectal cancer (mCRC).
First Author: Sang-A Kim